Selected article for: "causative agent and high risk"
Author: Hajjar, Ludhmila Abrahão; Costa, Isabela Bispo Santos da Silva; Rizk, Stephanie Itala; Biselli, Bruno; Gomes, Brenno Rizerio; Bittar, Cristina Salvadori; de Oliveira, Gisele Queiroz; de Almeida, Juliano Pinheiro; de Oliveira Bello, Mariana Vieira; Garzillo, Cibele; Leme, Alcino Costa; Elena, Moizo; Val, Fernando; de Almeida Lopes, Marcela; Lacerda, Marcus Vinícius Guimarães; Ramires, José Antonio Franchini; Kalil Filho, Roberto; Teboul, Jean-Louis; Landoni, Giovanni
Title: Intensive care management of patients with COVID-19: a practical approach
  • Cord-id: vagzvuny
  • Document date: 2021_2_18
    • ID: vagzvuny
    Snippet: SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), is responsible for the largest pandemic facing humanity since the Spanish flu pandemic in the early twentieth century. Since there is no specific antiviral treatment, optimized support is the most relevant factor in the patient's prognosis. In the hospital setting, the identification of high-risk patients for clinical deterioration is essential to ensure access to intensive treatment of severe conditions in a timely manner.
    Document: SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), is responsible for the largest pandemic facing humanity since the Spanish flu pandemic in the early twentieth century. Since there is no specific antiviral treatment, optimized support is the most relevant factor in the patient's prognosis. In the hospital setting, the identification of high-risk patients for clinical deterioration is essential to ensure access to intensive treatment of severe conditions in a timely manner. The initial management of hypoxemia includes conventional oxygen therapy, high-flow nasal canula oxygen, and non-invasive ventilation. For patients requiring invasive mechanical ventilation, lung-protective ventilation with low tidal volumes and plateau pressure is recommended. Cardiovascular complications are frequent and include myocardial injury, thrombotic events, myocarditis, and cardiogenic shock. Acute renal failure is a common complication and is a marker of poor prognosis, with significant impact in costs and resources allocation. Regarding promising therapies for COVID-19, the most promising drugs until now are remdesivir and corticosteroids although further studies may be needed to confirm their effectiveness. Other therapies such as, tocilizumab, anakinra, other anti-cytokine drugs, and heparin are being tested in clinical trials. Thousands of physicians are living a scenario that none of us have ever seen: demand for hospital exceed capacity in most countries. Until now, the certainty we have is that we should try to decrease the number of infected patients and that an optimized critical care support is the best strategy to improve patient’s survival.

    Search related documents:
    Co phrase search for related documents
    • long duration and low quality: 1, 2, 3
    • long duration and low quality evidence: 1
    • long duration and lung function: 1, 2, 3
    • long duration and lung inflammation: 1
    • long duration and lung injury: 1
    • low income and lung compliance: 1
    • low income and lung function: 1, 2, 3
    • low income and lung inflammation: 1, 2, 3, 4
    • low income and lung injury: 1, 2, 3, 4
    • low income and lung protective: 1, 2
    • low quality and lung alveolar damage: 1
    • low quality and lung function: 1, 2, 3, 4, 5
    • low quality and lung inflammation: 1, 2
    • low quality and lung injury: 1, 2, 3, 4
    • low quality and lung protective: 1, 2
    • lung function and lv filling: 1
    • lung function and lv left ventricle: 1
    • lung inflammation and lv filling: 1
    • lung inflammation and lv left ventricle: 1, 2